November 2025 in “International Journal of Recent Innovations in Medicine and Clinical Research” Understanding different types of hair loss helps in accurate diagnosis and treatment.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib works better in adolescents than adults for treating severe alopecia areata.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata.
October 2025 in “Journal of Skin and Sexually Transmitted Diseases” Alopecia areata patients often have undetected thyroid issues, so routine thyroid screening is recommended.
September 2025 in “Meditsinskiy sovet = Medical Council” Atopic dermatitis significantly increases the risk of alopecia areata, especially in children.
September 2025 in “Dermatology and Therapy” Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
September 2025 in “Journal of Dhaka Medical College” Lower vitamin D levels are linked to more severe alopecia areata.
August 2025 in “Frontiers in Immunology” Bullous pemphigoid, intrahepatic cholangiocarcinoma, and alopecia areata may share immune-related causes.
July 2025 in “Berkala Ilmu Kesehatan Kulit dan Kelamin” Alopecia areata in children shows varied symptoms and may involve nails, needing further evaluation for other health issues.
Dupilumab may cause hair loss, so patients should be monitored.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
July 2025 in “Pakistan Journal of Intensive Care Medicine” Clobetasol propionate 0.05% ointment is more effective than tacrolimus 0.1% ointment for treating alopecia areata.
Consider cultural practices and barriers for effective alopecia areata treatment.
June 2025 in “Reports of Vinnytsia National Medical University” Men with alopecia areata tend to have larger limb and trunk circumferences than healthy men.
June 2025 in “Reports of Morphology” Body structure can help identify alopecia areata in Ukrainian men, but not predict its course.
CD4 T cells need IFN-γ to cause hair loss in alopecia areata.
Histopathological confirmation is crucial for accurately diagnosing challenging alopecia areata cases.
April 2025 in “International Journal of Homoeopathic Sciences” Carcinosin, a homeopathic remedy, helped a young girl with alopecia areata regrow hair and reduce psychological symptoms.
April 2025 in “International Journal of Homoeopathic Sciences” Homeopathic treatment helped a girl regrow hair after other treatments failed.
April 2025 in “Egyptian journal of Immunology” Calprotectin levels are higher in alopecia areata patients, indicating systemic inflammation.
March 2025 in “Pakistan Journal of Health Sciences” Intralesional steroids improve Alopecia Areata, and trichoscopy effectively tracks this improvement.
March 2025 in “SKIN The Journal of Cutaneous Medicine” Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.
February 2025 in “Revista Eletrônica Acervo Saúde” Triamcinolone hexacetonide is effective but has side effects, while PRP and minoxidil are safer alternatives for treating alopecia areata.
January 2025 in “Acta Dermato Venereologica” Mothers with alopecia areata have a higher risk of adverse birth outcomes.
January 2025 in “Вопросы современной педиатрии” Janus kinase inhibitors effectively treat alopecia areata but may cause relapses and have long-term safety concerns.
January 2025 in “International Journal of Dermatology Sciences” Nail changes in alopecia areata are common and may indicate severity and genetic risk.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.